From studies advancing spine treatment to new techniques in stem cell procedures, here are seven updates on biologics so far this year:
1. Peter Fields, MD, director of OrthoRegen in Santa Monica, Calif., is offering a stem cell therapy that combines four regenerative orthopedic procedures, according to a Jan. 4 announcement.
2. Richmond-based OrthoVirginia's Adam Crowl, MD, performed the first spinal fusion in a clinic with the ViBone Moldable cell bone matrix, according to a Jan. 12 news release.
3. Orthobiologics company Bioventus launched its initial public offering Feb. 4.
4. DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, completed construction on its 25,000-square-foot headquarters in Salt Lake City.
5. Patients injected with stem cells derived from their own bone marrow saw improvement in motor functions after spinal cord injuries, a study from New Haven, Conn.-based Yale University found.
6. UC Davis Health in Sacramento, Calif., on March 1 announced the launch of the first FDA-approved human clinical trial using stem cells before birth to treat spina bifida, a defect that occurs when the spine and spinal cord do not form properly.
7. The global regenerative medicine market is projected to reach $39 million by 2030, up from $8.2 million in 2019, according to market research company P&S Intelligence.